ArticlePharmacoEconomics - open2024

A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France.

Paul Casabianca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.